论文信息 - Inotuzumab Ozogamicin Versus Standard of Care for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Phase 3 Randomized INO-Vate Trial: Outcomes By Salvage Treatment Phase - 字舞流文

Inotuzumab Ozogamicin Versus Standard of Care for Relapsed/Refractory Acute Lymphoblastic Leukemia in the Phase 3 Randomized INO-Vate Trial: Outcomes By Salvage Treatment Phase

M. Liedtke | H. Kantarjian | E. Jabbour | W. Stock | D. DeAngelo | S. O'brien | A. Advani | M. L. Paccagnella | E. Vandendries | N. Gökbuget | M. Stelljes | Tao Wang | Kongming Wang | B. Sleight